These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 194776)

  • 21. Cell mediated immunity during infectious mononucleosis to Epstein-Barr virus associated antigens.
    Periman P; Levine PH; Ablashi DV; Royston I
    Int J Cancer; 1977 Oct; 20(4):506-11. PubMed ID: 199544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphocyte sensitization to basic protein of brain in malignant neoplasia: experiments with serotonin and related compounds.
    Field EJ; Caspary EA; Carnegie PR
    Nature; 1971 Sep; 233(5317):284-6. PubMed ID: 4106472
    [No Abstract]   [Full Text] [Related]  

  • 23. Relationship between lymphocyte proliferation and migration inhibitory factor production in response to autologous tumor extract in cancer patients.
    Akiyoshi T; Miyazaki S; Koba F; Kawaguchi M; Tsuji H
    Gan; 1981 Dec; 72(6):988-91. PubMed ID: 6210594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leukocyte migration inhibition response to various antigen preparations of autologous and homologous breast cancer in patients with primary breast cancer.
    Fukuda M; Wanebo HJ; Tsuei L; Sarkar NH
    J Natl Cancer Inst; 1979 Nov; 63(5):1161-9. PubMed ID: 91696
    [No Abstract]   [Full Text] [Related]  

  • 25. [Specific delayed hypersensitivity to Epstein-Barr virus: in vitro study by leukocyte migration inhibition].
    Szigeti R; Timár L; Knoll J; Kuti D; Révész T
    Orv Hetil; 1980 May; 121(19):1121-4. PubMed ID: 6251414
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of different Epstein-Barr virus-determined antigens (EBNA, EA, and VCA) on the leukocyte migration of healthy donors and patients with infectious mononucleosis and certain immunodeficiencies.
    Szigeti R; Masucci MG; Henle W; Henle G; Purtilo D; Klein G
    Clin Immunol Immunopathol; 1982 Jan; 22(1):128-38. PubMed ID: 6288294
    [No Abstract]   [Full Text] [Related]  

  • 27. [Modification of a micromethod for determining leukocyte migration inhibition and its significance in oncological patients].
    Kochetkova VA
    Lab Delo; 1980; (12):744-6. PubMed ID: 6163894
    [No Abstract]   [Full Text] [Related]  

  • 28. [On the immunologic sensitizability of tumor patients].
    Hegemann F
    Arch Geschwulstforsch; 1968; 32(4):339-52. PubMed ID: 4308112
    [No Abstract]   [Full Text] [Related]  

  • 29. Lack of correlation between carcinoembryonic antigen content of tumor extracts and leukocyte migration reactivity of tumor patients.
    Matzku S; Zöller M; Schulz U; Dietze W; Barth HO; Saeger HD; Price MR
    J Natl Cancer Inst; 1980 Jun; 64(6):1345-8. PubMed ID: 6929372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Migration inhibitory test and its clinical aspects].
    Dobozy A; Hunyadi J; Simon N
    Berufsdermatosen; 1973 Aug; 21(4):137-51. PubMed ID: 4583667
    [No Abstract]   [Full Text] [Related]  

  • 31. Inhibition of leukocyte migration by human tumors. Effect on patient survival.
    Wolberg WH
    Arch Surg; 1974 Aug; 109(2):211-4. PubMed ID: 4367758
    [No Abstract]   [Full Text] [Related]  

  • 32. [Immunobiology of cancer].
    Oettgen HF
    Arch Klin Exp Ohren Nasen Kehlkopfheilkd; 1973; 205(1):21-36. PubMed ID: 4349192
    [No Abstract]   [Full Text] [Related]  

  • 33. [Immuno-oncologic monitoring of patients with bronchial carcinoma. IV. Aspects of the immunocompetence system].
    Mancuso M; Leonardo E; Sanfilippo B; Dogliotti C; De Simone M; De Bernochi P; Maggi G
    Minerva Med; 1985 Mar; 76(13):619-26. PubMed ID: 3873024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum migration inhibitory activity against macrophages and tumor cells.
    D'Silva H; Cohen M; Yoshida T; Cohen S
    Clin Immunol Immunopathol; 1982 Apr; 23(1):77-85. PubMed ID: 6807592
    [No Abstract]   [Full Text] [Related]  

  • 35. Serum associated leucocyte locomotion inhibition and leucocyte motility in malignant melanoma: effect of BCG treatment.
    Zielinski C; Pehamberger H; Endler AT; Knapp W
    Clin Exp Immunol; 1979 Oct; 38(1):92-8. PubMed ID: 393441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukocyte migration inhibition assay of tumor immunity in patients with cervical squamous cell carcinoma.
    Rivera ES; Hersh EM; Bowen JM; Barnett JW; Wharton T; Murphy SG
    Cancer; 1979 Jun; 43(6):2297-305. PubMed ID: 455220
    [No Abstract]   [Full Text] [Related]  

  • 37. Improvement of impaired leukocyte migration inhibition by thymosin in patients with head and neck squamous carcinoma.
    Wolf GT; Kerney SE; Chretien PB
    Am J Surg; 1980 Oct; 140(4):531-7. PubMed ID: 6999927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phytohemagglutinin-inhibition of the leucocyte migration in patients with breast carcinoma: correlation between clinical stage and immunocompetence.
    Pacheco-Rupil B; Depiante-Depaoli M; Treviño E; Bengolea O
    Cell Mol Biol; 1982; 28(1):73-7. PubMed ID: 7083279
    [No Abstract]   [Full Text] [Related]  

  • 39. [Oncology. Demonstration of tumor antigens in tumor tissue and in serum of patients with bronchial carcinoma].
    Gropp C; Preisser P; Lehmann FG; Ax W; von Kleist S; Havemann K
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1188-91. PubMed ID: 77099
    [No Abstract]   [Full Text] [Related]  

  • 40. Letter: The use of the cell migration inhibition test.
    Spitler LE
    J Immunol; 1974 Jan; 112(1):436. PubMed ID: 4590827
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.